These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 17983259)

  • 41. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    Deeks JJ; Smith LA; Bradley MD
    BMJ; 2002 Sep; 325(7365):619. PubMed ID: 12242171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis.
    Hirayama A; Tanahashi N; Daida H; Ishiguro N; Chachin M; Sugioka T; Kawai S;
    Circ J; 2014; 78(1):194-205. PubMed ID: 24152722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.
    Tsuji S; Miyoshi H; Tomita T; Nakase T; Hamada M; Oomae T; Tsumoto C; Hirata Y; Iguchi M; Edogawa S; Kawai H; Yoshikawa H
    Mod Rheumatol; 2012 Jun; 22(3):353-62. PubMed ID: 21904784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
    Fenton C; Keating GM; Wagstaff AJ
    Drugs; 2004; 64(11):1231-61. PubMed ID: 15161329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
    Cryer B; Luo X; Assaf AR; Sands G; Mardekian J
    Curr Med Res Opin; 2011 Feb; 27(2):295-302. PubMed ID: 21142617
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT; Pucino F; Resman-Targoff BH
    J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
    Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials.
    Essex MN; Zhang RY; Berger MF; Upadhyay S; Park PW
    Expert Opin Drug Saf; 2013 Jul; 12(4):465-77. PubMed ID: 23506230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Kristensen LE; Jakobsen AK; Askling J; Nilsson F; Jacobsson LT
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1137-49. PubMed ID: 25623277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial.
    Choi IA; Baek HJ; Cho CS; Lee YA; Chung WT; Park YE; Lee YJ; Park YB; Lee J; Lee SS; Yoo WH; Song JS; Kang SW; Kim HA; Song YW
    BMC Musculoskelet Disord; 2014 Nov; 15():375. PubMed ID: 25403311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclooxygenase-2 specificity and its clinical implications.
    Lefkowith JB
    Am J Med; 1999 May; 106(5B):43S-50S. PubMed ID: 10390127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.